Which drug first? study seeks best order for neuroendocrine tumor therapy

NCT ID NCT07534371

Ongoing Knowledge-focused Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at 500 people with advanced neuroendocrine tumors to see if starting with surufatinib or somatostatin analogs leads to better outcomes. Researchers will compare how long the cancer is controlled with each sequence. The goal is to provide real-world evidence to guide treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: surufatinib and somatostatin analogs (octreotide or lanreotide)
What this could lead to: If successful, this study could identify the best order of treatments for advanced neuroendocrine tumors, helping doctors personalize care and potentially extend the time patients live without their cancer growing.
What could go wrong: This is a retrospective study, meaning it looks back at past data, not a controlled experiment. Results may be influenced by factors like patient selection or incomplete records, so they cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE TUMORS

Contacts and locations

Locations

West China Hospital, Sichuan University

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.